Professor, Department of Biochemistry & Medical Genetics
Senior Scientist, Research Institute in Oncology and Hematology
Co-Director, Manitoba Tumour Bank
Predicting accurately if tumours will respond to treatment is an important goal of personalized approaches to cancer diagnosis and treatment to ensure the best possible outcome for breast cancer patients. The aim of the proposed research is to develop more accurate predictors of prognosis and treatment by studying changes on the estrogen receptor (ER), which is the target of current treatments and prevention options. However more than half of ER+ tumours are resistant to hormonal therapies. My research team previously discovered that combinations of phosphorylation on ER are more accurate biomarkers of prognosis and therapy response. Our work suggests that an epigenetic code, including multiple post-translational modifications, exists for the ER, which determines the balance of ligand dependent and independent function. Importantly, key enzymes that are involved in maintaining the ER epigenetic code will be viable treatment and possibly prevention targets.
Due to my research focus on PTM of ER, other steroid receptors and their coregulators, I am highly interested in being part of the Manitoba Epigenetic Network.
ON6020 CancerCare Manitoba